> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Developing Pneumonia Drugs
- URL: https://www.fdaweb.com/guide-on-developing-pneumonia-drugs/
- Published: 2020-06-25T12:00:00.000Z
- Updated: 2026-09-14T16:19:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147089

*Federal Register* notice: FDA has made available a final guidance entitled “Community-Acquired Bacterial Pneumonia (CABP): Developing Drugs for Treatment.” The document clarifies the time to assess the primary efficacy endpoint (Day 4), updates to the CABP trial population based on the Pneumonia Patient Outcomes Research Team scores, evaluation of intravenous drug formulations, and analysis populations. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-06-25/pdf/2020-13746.pdf?ref=fdaweb.com).